NemoClaw Knowledge Wiki

Ritonavir Polymorph Crisis: Unraveling the Mystery of a Failing HIV Drug

3 min read

Ritonavir Polymorph Crisis: Unraveling the Mystery of a Failing HIV Drug

Generated: 2026-04-30 · API: Gemini 2.5 Flash · Modes: Summary

Ritonavir Polymorph Crisis: Unraveling the Mystery of a Failing HIV Drug

Clip title: The disaster I never imagined having to worry about Author / channel: Veritasium URL: https://www.youtube.com/watch?v=ksn5yrsC3Wg

Summary

The video details the perplexing case of Ritonavir, a crucial HIV medication introduced in 1996, which suddenly began failing quality control tests two years later. Despite being a “miracle drug” that had consistently passed dissolution tests for 240 consecutive batches, capsules at Abbott Laboratories in Chicago started turning white, cloudy, and filled with mysterious needle-like crystals. Intensive investigations, including destroying entire batches and deep-cleaning production lines, failed to identify the cause. Even attempts to recreate the drug in a lab, or produce it at an entirely new facility in Italy, eventually succumbed to the same issue, as the problem mysteriously spread.

Researchers initially struggled to understand how a drug with a known chemical composition and a meticulously controlled manufacturing process could spontaneously change. The mystery was eventually solved by drawing parallels to a 19th-century debate between chemists Justus von Liebig and Friedrich Wöhler, who discovered that compounds could have the exact same elemental composition but vastly different properties due to the arrangement of their atoms (isomers). In the case of Ritonavir, scientists discovered the drug was undergoing a transformation into a new “polymorph” – an alternative crystalline structure of the same chemical compound.

This new polymorph, identified as Form II, was significantly more stable and less soluble than the original Form I, rendering the medication ineffective in the body. Unlike the example of chocolate polymorphs, which can be managed through tempering (melting and controlled cooling to encourage desired crystal forms), Ritonavir Form II was virtually irreversible. A tiny speck of Form II could act as a “seed crystal,” dramatically lowering the energy barrier for Form I to convert into the more stable Form II. These seed crystals could become airborne, contaminating entire factories, spreading via personnel to other sites, and quickly converting new batches of the drug.

Ultimately, Abbott Laboratories was forced to abandon the effective capsule formulation of Ritonavir and revert to an older, less ideal liquid version with greater side effects. The incident highlighted a critical vulnerability in pharmaceutical manufacturing: the unpredictable nature of polymorphism. Such transformations, while rare, can affect any drug, potentially causing widespread supply interruptions and rendering life-saving medications ineffective. The Ritonavir crisis underscored the urgent need for extensive research into polymorphs to better understand, detect, and prevent these “disappearing polymorph” phenomena from occurring in other crucial medicines.

Video Description & Links

Graph View

Backlinks